SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma

NCT00089648 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
61
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Pfizer